MedTrace Logo

Safety Study of Specific Tumor Target Drug Plus Immune System Therapy in Patients With Kidney Cancer

NCT00440973 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2016-03-17

No results posted yet for this study

Summary

The purpose of this study is to determine if the combination of therapy to strengthen the immune system (Interleukin - 2) plus a specific tumor target therapy (Bevacizumab) can prolong the time between the start of treatment and disease progression, decrease tumor size, as well as determine if the combination therapy is safer and less toxic than the standard treatment for renal cell carcinoma.

Conditions

  • Carcinoma, Renal Cell

Interventions

DRUG

Bevacizumab

monoclonal antibody with anti-angiogenesis properties used as chemotherapy

DRUG

Interleukin-2

immunotherapy - cytokine signaling molecule used as an immune system regulator to trigger T \& B lymphocyte proliferation

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • The Methodist Hospital Research Institute

    lead OTHER

Principal Investigators

  • Robert J. Amato, D.O. · Baylor College of Medicine - Methodist Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2007-10-31
Completion
2007-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00440973 on ClinicalTrials.gov